Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen
Journal of Allergy and Clinical Immunology(1997)
Abstract
Background: Atopic allergens produced by recombinant DNA methods are promising tools for diagnosis and therapy of Type I allergy. To evaluate the immunologic properties of these molecules, it is necessary to compare them with natural allergens in vitro and in vivo. Objective: The study was carried out to determine whether the potency of recombinant Bet v 1 (rBet v 1) is comparable to that of natural Bet v 1 (nBet v 1) in inducing allergic reactions in the nose and bronchi. Methods: Thirteen patients allergic to birch pollen with bronchial asthma and/or rhinitis were investigated. Skin prick tests and nasal and bronchial challenges were performed with rBet v 1 and nBet v 1. Results: In patients allergic to birch pollen, both allergens induced comparable skin reactions. In subjects with rhinitis rBet v 1 was equally potent in inducing nasal reactions (mean PD
+60NR ± SD, 10.48 ± 17.42 μg vs 7.98 ± 8.9 μg, p > 0.05). In patients with asthma, rBet v 1 was equally potent in inducing bronchial reactions (PD
20FEV
1, 0.81 ± 1.74 μg vs 0.62 ± 1.44 μg, p > 0.05) as nBet v 1. Conclusion: No significant differences were observed between natural and recombinant allergen. We conclude that allergens produced by recombinant techniques can induce typical allergic reactions in important target organs of Type I allergy: the nose and bronchi. (J Allergy Clin Immunol 1997;99:354-9.)
MoreTranslated text
Key words
Type I allergy,recombinant allergen,Bet v 1,bronchial asthma,provocation test
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined